Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 13, Number 1—January 2007

Research

Vaccine Effectiveness Estimates, 2004–2005 Mumps Outbreak, England

Cheryl Cohen*1Comments to Author , Joanne M. White†, Emma J. Savage†, Judith R. Glynn*, Yoon Choi†, Nick Andrews†, David Brown†, and Mary E. Ramsay†
Author affiliations: *London School of Hygiene and Tropical Medicine, London, United Kingdom; †Health Protection Agency Centre for Infections, London, United Kingdom; 1Current affiliations: National Institute for Communicable Diseases, Johannesburg, South Africa, and University of the Witwatersrand School of Public Health, Parktown, South Africa

Main Article

Table 1

Characteristics of reviewed mumps case-patients by number of doses of measles, mumps, rubella vaccine received

CharacteristicNo. doses received (%)
p value*
012
Age group, y
  211 (84.6)2 (15.4)
  5–651 (83.6)5 (8.2)5 (8.2)<0.001†
  7–852 (61.2)11 (12.9)22 (25.9)
  9–1035 (39.8)16 (18.2)37 (42.1)
  11–1214 (21.5)18 (27.7)33 (50.8)
Birth cohort‡
  1993–199531 (30.1)25 (24.3)47 (45.6)<0.001†
  1995–199742 (48.8)12 (14.0)32 (37.2)
  1997–199945 (66.2)8 (11.8)15 (22.1)
  1999–200134 (81.0)5 (11.9)3 (7.1)
  2001–200311 (84.6)2 (15.4)
Area of residence
  Outside London143 (51.3)46 (16.5)90 (32.3)0.1
  London18 (64.3)6 (21.4)4 (14.3)
  Data not available2 (40.0)3 (60.0)
Sex
  Female63 (48.8)19 (14.7)47 (36.4)0.2
  Male100 (55.0)32 (17.6)50 (27.5)
  Data not available1 (100.0)
Total163 (52.2)52 (16.7)97 (31.1)

*Fisher exact test.
†Children <2 years of age and 2001–2003 birth cohorts excluded for age group and birth cohort, respectively.
‡Birth cohorts for 2 consecutive school years (i.e., children born October 1–September 30 of the following year).

Main Article

1Current affiliations: National Institute for Communicable Diseases, Johannesburg, South Africa, and University of the Witwatersrand School of Public Health, Parktown, South Africa

TOP